Agenus (AGEN) Projected to Post Earnings on Monday

Agenus (NASDAQ:AGEN) is expected to announce its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect the company to announce earnings of $2.63 per share and revenue of $80.3870 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The business had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Stock Performance

NASDAQ AGEN opened at $3.98 on Friday. Agenus has a one year low of $1.38 and a one year high of $7.34. The company has a market capitalization of $126.82 million, a price-to-earnings ratio of -0.56 and a beta of 1.43. The company’s 50-day simple moving average is $4.17 and its two-hundred day simple moving average is $4.46.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. purchased a new stake in Agenus in the first quarter valued at about $88,000. AQR Capital Management LLC grew its position in Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Agenus during the 1st quarter worth approximately $58,000. JPMorgan Chase & Co. increased its stake in Agenus by 608.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 67,530 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Agenus in the second quarter worth $1,976,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AGEN shares. Zacks Research raised shares of Agenus to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen cut Agenus from a “buy” rating to a “hold” rating in a research report on Sunday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Agenus in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.